(PharmaNewsWire.Com, June 11, 2019 ) According to the new market research report “Pen Needles Market by Type (Standard Pen Needles and Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP-1, Growth Hormone, and Others), Mode of Purchase (Retail, Non-Retail) — Global Forecasts to 2023, published by MarketsandMarkets™
Growth in the Pen Needles Market is mainly driven by factors such as the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries. The growing preference for biosimilar drugs is another factor providing a wide range of growth opportunities for key players in the market.
The standard Pen Needles segment is expected to account for the largest share of the market in 2018
On the basis of type, the market is segmented into standard and safety Pen Needles. In 2018, the standard Pen Needles segment is expected to account for the largest share of the Pen Needles Market. Growth in this market is attributed to the low cost of standard Pen Needles.
Browse and in-depth TOC on “Pen Needles Market”
87 — Tables
46 — Figures
144 — Pages
The insulin therapy segment is expected to grow at the highest CAGR during the forecast period
On the basis of therapy, the Pen Needles Market is categorized into insulin therapy, glucagon-like peptide-1 (GLP-1) therapy, growth hormone therapy, and other therapies. The insulin therapy segment is expected to grow at the highest CAGR during the forecast period due to the high and growing diabetic population globally.
Europe dominated the Pen Needles Market in 2018
Europe is expected to dominate the Market in 2018. The large share of the European Pen Needles Market can primarily be attributed to the high diabetes expenditure and reimbursement in Germany, NHS support and access to Pen Needles at a subsidized cost in the UK, high insurance coverage in France, and supportive regulations in Spain.
The key players in the Pen Needles Market are Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), HTL-STREFA S.A. (Poland), Terumo Corporation (Japan), and Owen Mumford (UK).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: